Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272531 | 0.93 | CYP3A4 (0.40) | NPC1RAB9ASMN1; SMN2HSD17B10CYP2D6 | |
| SCHEMBL4437979 | 0.91 | CDK2 (0.38) | NPC1RAB9ASMN1; SMN2HSD17B10CYP3A4 | |
| SCHEMBL4263969 | 0.86 | CYP2D6 (0.42) | NPC1RAB9ASMN1; SMN2HSD17B10CYP2D6 | |
| SCHEMBL4434419 | 0.82 | CDK2 (0.40) | HSD17B10CYP3A4CDK2CYP2C9CYP19A1 | |
| SCHEMBL3267198 | 0.79 | CDK2 (0.38) | CDK2HTR2AHTR2CHTR2B | |
| SCHEMBL16631651 | 0.78 | CYP2D6 (0.37) | NPC1RAB9ASMN1; SMN2HSD17B10CYP2D6 | |
| SCHEMBL3266814 | 0.76 | KCNA3 (0.47) | CDK2ALDH1A1 | |
| SCHEMBL3268390 | 0.76 | KCNA3 (0.52) | SMN1; SMN2CDK2ALDH1A1LMNATSHR | |
| SCHEMBL4268041 | 0.76 | GABRP (0.38) | NPC1RAB9ASMN1; SMN2HSD17B10GABRP | |
| SCHEMBL3272371 | 0.75 | KCNA3 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567443-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-28 | — | — | CN | disclosed |
| CN-115925679-A | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-07 | — | — | CN | disclosed |
| EP-3239143-B1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEMICAL LTD (KR) | 2023-03-22 | — | — | EP | disclosed |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2022-05-05 | — | — | US | disclosed |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | LG CHEM. LTD. (KR) | 2022-03-01 | — | — | US | disclosed |
| CN-107567443-A | biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2018-01-09 | — | — | CN | disclosed |
| US-20170349594-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2017-12-07 | — | — | US | disclosed |
| EP-3239143-A2 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG Chem, Ltd. (KR) | 2017-11-01 | — | — | EP | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | NPC1 1654/4885RAB9A 2293/4885SMN1; SMN2 3448/4885 |
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | NPC1 4653/4885RAB9A 3263/4885SMN1; SMN2 3200/4885 |
| US-20160368918-A1 | SYK INHIBITORS | SYK, BTK, LYN | NPC1 4638/4885RAB9A 3273/4885SMN1; SMN2 3271/4885 |
| US-20170349594-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | NPC1 1654/4885RAB9A 2293/4885SMN1; SMN2 3448/4885 |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | GPR119, GPR88, FFAR1 | NPC1 640/4885RAB9A 2731/4885SMN1; SMN2 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.